Endoscopic Ultrasound-guided Fine-needle Biopsy for Tissue Sampling of Biliary Strictures: a Multicenter Prospective Study
NCT ID: NCT06614452
Last Updated: 2024-09-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
45 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-09-10
Study Completion Date
2025-10-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After the disappointing results of first-generation reverse bevel fine-needle biopsy (FNB) needles, newer 'third generation' endoscopic ultrasound (EUS) needles were developed, known as the "end-cutting" needles. These needle types have shown excellent diagnostic accuracy (\>90%) in pancreatic masses and several other lesions, even without rapid on site evaluation (ROSE) and are not associated with increased adverse event incidence . The main design of end-cutting FNB needles are the Franseen type, which has three symmetrically distributed needle points and cutting edges, and the Fork-tip type which has 2 protruding asymmetrical sharp points and six distal cutting edges; however, other end-cutting needles are currently available such as the three-prong asymmetric tip needle and the Menghini tip needle.
Given the significant increase in diagnostic accuracy and sensitivity observed in other abdominal lesions, these needles are expected to improve the diagnostic outcomes of EUS-FNB of "pure" biliary strictures although clinical data are still lacking.
The aim of this study is to ascertain the impact of end-cutting FNB needles in the diagnostic algorithm of biliary strictures in absence of a clear pancreatic or abdominal mass.
This is a multicenter international observational prospective study. Consecutive patients diagnosed with biliary strictures in absence of a pancreatic or abdominal mass will be assessed for eligibility.
Patients with jaundice requiring decompression, will undergo endoscopic retrograde cholangiopancreatography (ERCP) with tissue sampling (brushing and/or biopsy) and biliary drainage, preferably in the same session immediately after EUS-FNB.
Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the "slow-pull", the "dry suction", or the "wet suction", will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.
The ROSE will not be available in this study. Primary outcome will be diagnostic sensitivity of EUS-FNB and 45 patients will be prospectically enrolled.
Given the significant increase in diagnostic accuracy and sensitivity observed in other abdominal lesions, these needles are expected to improve the diagnostic outcomes of EUS-FNB of "pure" biliary strictures although clinical data are still lacking.
The aim of this study is to ascertain the impact of end-cutting FNB needles in the diagnostic algorithm of biliary strictures in absence of a clear pancreatic or abdominal mass.
This is a multicenter international observational prospective study. Consecutive patients diagnosed with biliary strictures in absence of a pancreatic or abdominal mass will be assessed for eligibility.
Patients with jaundice requiring decompression, will undergo endoscopic retrograde cholangiopancreatography (ERCP) with tissue sampling (brushing and/or biopsy) and biliary drainage, preferably in the same session immediately after EUS-FNB.
Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the "slow-pull", the "dry suction", or the "wet suction", will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.
The ROSE will not be available in this study. Primary outcome will be diagnostic sensitivity of EUS-FNB and 45 patients will be prospectically enrolled.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer
NCT01356030
Pancreaticobiliary Cancers
Jaundice
Bile Duct Obstruction
COMPLETED
NA
The Diagnostic Value of Combinatory EUS and ERCP in Unclear Lesions
NCT03504293
Neoplasms
Biliary Stricture
Biliary Tract Neoplasms
+1 more
COMPLETED
EUS-guided FNB-induced PANCREatitis Assessment
NCT07168863
Pancreatitis, Acute
EUS Guided Biopsy
RECRUITING
Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study
NCT02116322
Pancreatic Cancer
TERMINATED
NA
EUS-FNA for Patients Taking Anticoagulants Without Heparin Bridge
NCT02977650
Endoscopic Ultrasonography-guided Fine Needle Aspiration
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
INTRODUCTION Tissue sampling to establish the nature of a stricturing lesion represents a key step in the diagnostic work-up of biliary strictures. As already known, a significant proportion (70%-80%) of biliary strictures are malignant, higher in patients with a definitive mass lesion than in those without a mass on cross-sectional imaging (PMID: 23340062). Early diagnosis is thus important for directing patients to the proper therapeutic strategy. While transpapillary brush cytology or forceps biopsy after sphincterotomy during endoscopic retrograde cholangiopancreatography (ERCP) have been the standard sampling modality, endoscopic ultrasound (EUS)-tissue acquisition (TA) is a useful later addition to the diagnostic armamentarium. The pooled sensitivity of brush cytology and intraductal biopsies has been found to be 45% and 48.1% respectively, while the combination of the two only modestly increased the sensitivity to 59.4% (PMID: 25440678). On the contrary, EUS-TA has been reported to have a pooled diagnostic sensitivity of 83% for distal biliary strictures (PMID: 26422979). Moreover, the choice of the modality adopted would depend not only on the availability of expertise, but also on the location of the lesion and presence of jaundice. Indeed, EUS-TA has shown better sensitivity for distal lesions compared to proximal lesions (PMID: 26422979).
The performance of EUS-TA in peri-hilar strictures showed less favourable results. A 2020 prospective evaluation of EUS-fine-needle aspiration (FNA) in the diagnosis of biliary strictures (n=97, 46% hilar) showed an overall sensitivity of 75% (CI 64%-84%). Subgroup sensitivity and negative predictive value (NPV) reached 95% and 93% for distal lesions without stenting, whereas for the group of stented peri-hilar lesions this was much lower at 56% and 33% respectively (PMID: 33140008).
However, data on EUS-TA of biliary strictures are based only to EUS-FNA studies whereas data on EUS-fine-needle biopsy (FNB) are lacking in this setting.
In the last three decades, the evolution of needles has undergone a remarkable change and is constantly under development, by designing innovative tip designs to allow for larger histological specimens with preserved tissue architecture, along with use of tissue for genomic profiling and organoids development that are very important in the era of oncological personalized medicine. As a result, the current era has seen a decisive shift from FNA to FNB needles.
EUS-FNA needles have limitations that are well known: their diagnostic performance is dependent on a cytopathologist to render a rapid on-site evaluation (ROSE), no provision of a histological core tissue is possible, and insufficient tissue for risk stratification to tailor anti-cancer therapy.
After the disappointing results of first-generation reverse bevel FNB needles, newer 'third generation' EUS needles were developed, known as the "end-cutting" needles. These needle types have shown excellent diagnostic accuracy (\>90%) in pancreatic masses and several other lesions, even without ROSE and are not associated with increased adverse event incidence (PMID: 37591258; PMID: 36990125; PMID: 35124072). The main design of end-cutting FNB needles are the Franseen type, which has three symmetrically distributed needle points and cutting edges, and the Fork-tip type which has 2 protruding asymmetrical sharp points and six distal cutting edges; however, other end-cutting needles are currently available such as the three-prong asymmetric tip needle and the Menghini tip needle.
Given the significant increase in diagnostic accuracy and sensitivity observed in other abdominal lesions, these needles are expected to improve the diagnostic outcomes of EUS-FNB of "pure" biliary strictures although clinical data are still lacking.
The aim of this study is to ascertain the impact of end-cutting FNB needles in the diagnostic algorithm of biliary strictures in absence of a clear pancreatic or abdominal mass.
STUDY DESIGN Multicenter international observational prospective study. This study will be conducted according to the principles and the recommendations of the 2013 Declaration of Helsinki.
STUDY PATIENTS Consecutive patients diagnosed with biliary strictures in absence of a pancreatic or abdominal mass will be assessed for eligibility. Diagnosis of biliary strictures will be performed according to current guidelines (PMID: 37307900).
Patients with jaundice requiring decompression, will undergo ERCP with tissue sampling (brushing and/or biopsy) and biliary drainage, preferably in the same session immediately after EUS-FNB.
Inclusion criteria
* Age ≥18 years
* Suspicious biliary stricture in absence of an abdominal mass at cross-sectional imaging
* Distal and peri-hilar biliary strictures
* Informed consent provided by the patient or the closest relative
Exclusion criteria
* Presence of a pancreatic or abdominal mass structuring the common bile duct
* EUS not feasible
* Known bleeding disorder that cannot be sufficiently corrected with fresh frozen plasma (FFP)
* Use of anticoagulants that cannot be discontinued
* INR \>1.5 or platelet count \<50.000
* Pregnancy
PROCEDURAL TECHNIQUE Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the "slow-pull", the "dry suction", or the "wet suction", will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.
The rapid-on site cytological evaluation (ROSE) will not be available in this study.
ENDPOINTS Primary Endpoint Primary outcome will be diagnostic sensitivity of EUS-FNB, defined as true positives/true positives + false negatives.
Secondary Endpoints
* Sample adequacy, defined as the ability to procure histological samples adequate for diagnostic interpretation. A histologic specimen will be defined as an architecturally intact piece of tissue from the target lesion (PMID: 29074447).
* Diagnostic accuracy (defined as true positive + true negative/ total number of patients). The gold standard for the final diagnosis will be the pathological report in the subset of patients undergoing surgery and the clinical follow-up for 6 months in non-surgical patients.
* Diagnostic specificity, defined as true negatives/true negatives+false positives
* Histological quality of the sample quantified using a score for tissue integrity and blood contamination of specimens validated elsewhere (PMID: 32433914)
* Yield of each needle pass
* Number of needle passes
* Adverse events, classified according to ASGE lexicon (PMID: 20189503). Postprocedural AEs will be investigated during follow-up with phone calls at 2 weeks after the procedure.
ENROLLMENT AND DROP-OUT Enrollment will be competitive between centers and will extend for a maximum period of 1 year after local Ethic Committee/IRB approval. Patients will be considered dropped-out in case of consent withdrawn or if lost before the end of follow-up.
SAMPLE SIZE CALCULATION AND STATISTICAL CONSIDERATIONS On the basis of a previous study (PMID: 33140008) reporting 75% sensitivity with EUS-FNA of biliary strictures, the study is designed to detect an increase in diagnostic yield with end-cutting FNB needles to 94.8%, as reported in a previous meta-analysis (PMID: 31579703).
Therefore, 45 patients will be required to have a 90% power to detect the target difference at a 0.025 significance level (adjusted for multiplicity considering the planned subgroup analysis between peri-hilar and distal biliary strictures) and expecting a drop-out rate of 10%. A 2:1 stratification according to the location of the biliary strictures will be considered; therefore, we expect to enroll 30 patients with distal biliary strictures and 15 patients with peri-hilar biliary strictures.
DATA COLLECTED General information
* Age (years)
* Sex (M/F)
* Charlson comorbidity index
* BMI Lesion information
* Location
* Imaging studies performed
* Lesion size (mm)
* Main pancreatic duct (MPD) dilation
* CBD caliber (mm) Procedural information
* Sampling route (stomach, duodenum)
* Number of passes
* Sampling technique (dry suction, wet suction, slow pull) Outcomes
* Adequacy at each pass
* Sensitivity
* Specificity
* Accuracy
* Quality of sample
* Surgery
* AEs
* Final diagnosis
The performance of EUS-TA in peri-hilar strictures showed less favourable results. A 2020 prospective evaluation of EUS-fine-needle aspiration (FNA) in the diagnosis of biliary strictures (n=97, 46% hilar) showed an overall sensitivity of 75% (CI 64%-84%). Subgroup sensitivity and negative predictive value (NPV) reached 95% and 93% for distal lesions without stenting, whereas for the group of stented peri-hilar lesions this was much lower at 56% and 33% respectively (PMID: 33140008).
However, data on EUS-TA of biliary strictures are based only to EUS-FNA studies whereas data on EUS-fine-needle biopsy (FNB) are lacking in this setting.
In the last three decades, the evolution of needles has undergone a remarkable change and is constantly under development, by designing innovative tip designs to allow for larger histological specimens with preserved tissue architecture, along with use of tissue for genomic profiling and organoids development that are very important in the era of oncological personalized medicine. As a result, the current era has seen a decisive shift from FNA to FNB needles.
EUS-FNA needles have limitations that are well known: their diagnostic performance is dependent on a cytopathologist to render a rapid on-site evaluation (ROSE), no provision of a histological core tissue is possible, and insufficient tissue for risk stratification to tailor anti-cancer therapy.
After the disappointing results of first-generation reverse bevel FNB needles, newer 'third generation' EUS needles were developed, known as the "end-cutting" needles. These needle types have shown excellent diagnostic accuracy (\>90%) in pancreatic masses and several other lesions, even without ROSE and are not associated with increased adverse event incidence (PMID: 37591258; PMID: 36990125; PMID: 35124072). The main design of end-cutting FNB needles are the Franseen type, which has three symmetrically distributed needle points and cutting edges, and the Fork-tip type which has 2 protruding asymmetrical sharp points and six distal cutting edges; however, other end-cutting needles are currently available such as the three-prong asymmetric tip needle and the Menghini tip needle.
Given the significant increase in diagnostic accuracy and sensitivity observed in other abdominal lesions, these needles are expected to improve the diagnostic outcomes of EUS-FNB of "pure" biliary strictures although clinical data are still lacking.
The aim of this study is to ascertain the impact of end-cutting FNB needles in the diagnostic algorithm of biliary strictures in absence of a clear pancreatic or abdominal mass.
STUDY DESIGN Multicenter international observational prospective study. This study will be conducted according to the principles and the recommendations of the 2013 Declaration of Helsinki.
STUDY PATIENTS Consecutive patients diagnosed with biliary strictures in absence of a pancreatic or abdominal mass will be assessed for eligibility. Diagnosis of biliary strictures will be performed according to current guidelines (PMID: 37307900).
Patients with jaundice requiring decompression, will undergo ERCP with tissue sampling (brushing and/or biopsy) and biliary drainage, preferably in the same session immediately after EUS-FNB.
Inclusion criteria
* Age ≥18 years
* Suspicious biliary stricture in absence of an abdominal mass at cross-sectional imaging
* Distal and peri-hilar biliary strictures
* Informed consent provided by the patient or the closest relative
Exclusion criteria
* Presence of a pancreatic or abdominal mass structuring the common bile duct
* EUS not feasible
* Known bleeding disorder that cannot be sufficiently corrected with fresh frozen plasma (FFP)
* Use of anticoagulants that cannot be discontinued
* INR \>1.5 or platelet count \<50.000
* Pregnancy
PROCEDURAL TECHNIQUE Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the "slow-pull", the "dry suction", or the "wet suction", will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.
The rapid-on site cytological evaluation (ROSE) will not be available in this study.
ENDPOINTS Primary Endpoint Primary outcome will be diagnostic sensitivity of EUS-FNB, defined as true positives/true positives + false negatives.
Secondary Endpoints
* Sample adequacy, defined as the ability to procure histological samples adequate for diagnostic interpretation. A histologic specimen will be defined as an architecturally intact piece of tissue from the target lesion (PMID: 29074447).
* Diagnostic accuracy (defined as true positive + true negative/ total number of patients). The gold standard for the final diagnosis will be the pathological report in the subset of patients undergoing surgery and the clinical follow-up for 6 months in non-surgical patients.
* Diagnostic specificity, defined as true negatives/true negatives+false positives
* Histological quality of the sample quantified using a score for tissue integrity and blood contamination of specimens validated elsewhere (PMID: 32433914)
* Yield of each needle pass
* Number of needle passes
* Adverse events, classified according to ASGE lexicon (PMID: 20189503). Postprocedural AEs will be investigated during follow-up with phone calls at 2 weeks after the procedure.
ENROLLMENT AND DROP-OUT Enrollment will be competitive between centers and will extend for a maximum period of 1 year after local Ethic Committee/IRB approval. Patients will be considered dropped-out in case of consent withdrawn or if lost before the end of follow-up.
SAMPLE SIZE CALCULATION AND STATISTICAL CONSIDERATIONS On the basis of a previous study (PMID: 33140008) reporting 75% sensitivity with EUS-FNA of biliary strictures, the study is designed to detect an increase in diagnostic yield with end-cutting FNB needles to 94.8%, as reported in a previous meta-analysis (PMID: 31579703).
Therefore, 45 patients will be required to have a 90% power to detect the target difference at a 0.025 significance level (adjusted for multiplicity considering the planned subgroup analysis between peri-hilar and distal biliary strictures) and expecting a drop-out rate of 10%. A 2:1 stratification according to the location of the biliary strictures will be considered; therefore, we expect to enroll 30 patients with distal biliary strictures and 15 patients with peri-hilar biliary strictures.
DATA COLLECTED General information
* Age (years)
* Sex (M/F)
* Charlson comorbidity index
* BMI Lesion information
* Location
* Imaging studies performed
* Lesion size (mm)
* Main pancreatic duct (MPD) dilation
* CBD caliber (mm) Procedural information
* Sampling route (stomach, duodenum)
* Number of passes
* Sampling technique (dry suction, wet suction, slow pull) Outcomes
* Adequacy at each pass
* Sensitivity
* Specificity
* Accuracy
* Quality of sample
* Surgery
* AEs
* Final diagnosis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Biliary Strictures
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EUS-FNB
Consecutive patients diagnosed with biliary strictures in absence of a pancreatic or abdominal mass will be assessed for eligibility.
Patients with jaundice requiring decompression, will undergo ERCP with tissue sampling (brushing and/or biopsy) and biliary drainage, preferably in the same session immediately after EUS-FNB.
Group Type
EXPERIMENTAL
EUS-FNB
Intervention Type
DEVICE
Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the "slow-pull", the "dry suction", or the "wet suction", will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.
The rapid-on site cytological evaluation (ROSE) will not be available in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EUS-FNB
Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the "slow-pull", the "dry suction", or the "wet suction", will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.
The rapid-on site cytological evaluation (ROSE) will not be available in this study.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* Suspicious biliary stricture in absence of an abdominal mass at cross-sectional imaging
* Distal and peri-hilar biliary strictures
* Informed consent provided by the patient or the closest relative
* Suspicious biliary stricture in absence of an abdominal mass at cross-sectional imaging
* Distal and peri-hilar biliary strictures
* Informed consent provided by the patient or the closest relative
Exclusion Criteria
* Presence of a pancreatic or abdominal mass structuring the common bile duct
* EUS not feasible
* Known bleeding disorder that cannot be sufficiently corrected with fresh frozen plasma (FFP)
* Use of anticoagulants that cannot be discontinued
* INR \>1.5 or platelet count \<50.000
* Pregnancy
* EUS not feasible
* Known bleeding disorder that cannot be sufficiently corrected with fresh frozen plasma (FFP)
* Use of anticoagulants that cannot be discontinued
* INR \>1.5 or platelet count \<50.000
* Pregnancy
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ospedali Riuniti di Foggia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Facciorusso
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedali Riuniti di Foggia
Foggia, FG, Italy
Site Status
RECRUITING
Università di Verona
Verona, VR, Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.
Reference Type
RESULT
Wani S, Muthusamy VR, McGrath CM, Sepulveda AR, Das A, Messersmith W, Kochman ML, Shah J. AGA White Paper: Optimizing Endoscopic Ultrasound-Guided Tissue Acquisition and Future Directions. Clin Gastroenterol Hepatol. 2018 Mar;16(3):318-327. doi: 10.1016/j.cgh.2017.10.020. Epub 2017 Oct 23. No abstract available.
Reference Type
RESULT
Fujii-Lau LL, Thosani NC, Al-Haddad M, Acoba J, Wray CJ, Zvavanjanja R, Amateau SK, Buxbaum JL, Calderwood AH, Chalhoub JM, Coelho-Prabhu N, Desai M, Elhanafi SE, Fishman DS, Forbes N, Jamil LH, Jue TL, Kohli DR, Kwon RS, Law JK, Lee JK, Machicado JD, Marya NB, Pawa S, Ruan W, Sawhney MS, Sheth SG, Storm A, Thiruvengadam NR, Qumseya BJ; (ASGE Standards of Practice Committee Chair, 2020-2023). American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology: summary and recommendations. Gastrointest Endosc. 2023 Nov;98(5):685-693. doi: 10.1016/j.gie.2023.06.005. Epub 2023 Jun 10.
Reference Type
RESULT
Gkolfakis P, Crino SF, Tziatzios G, Ramai D, Papaefthymiou A, Papanikolaou IS, Triantafyllou K, Arvanitakis M, Lisotti A, Fusaroli P, Mangiavillano B, Carrara S, Repici A, Hassan C, Facciorusso A. Comparative diagnostic performance of end-cutting fine-needle biopsy needles for EUS tissue sampling of solid pancreatic masses: a network meta-analysis. Gastrointest Endosc. 2022 Jun;95(6):1067-1077.e15. doi: 10.1016/j.gie.2022.01.019. Epub 2022 Feb 4.
Reference Type
RESULT
Carrara S, Rahal D, Khalaf K, Rizkala T, Koleth G, Bonifacio C, Andreozzi M, Mangiavillano B, Auriemma F, Bossi P, Balzarotti M, Facciorusso A, Staiano T, Maldi E, Spadaccini M, Colombo M, Fugazza A, Maselli R, Hassan C, Repici A. Diagnostic accuracy and safety of EUS-guided end-cutting fine-needle biopsy needles for tissue sampling of abdominal and mediastinal lymphadenopathies: a prospective multicenter series. Gastrointest Endosc. 2023 Aug;98(2):191-198. doi: 10.1016/j.gie.2023.03.018. Epub 2023 Mar 27.
Reference Type
RESULT
Facciorusso A, Crino SF, Fugazza A, Carrara S, Spadaccini M, Colombo M, Ramai D, Mangiavillano B, Chandan S, Gkolfakis P, Mohan B, Hassan C, Repici A. Comparative diagnostic yield of different endoscopic techniques for tissue sampling of upper gastrointestinal subepithelial lesions: a network meta-analysis. Endoscopy. 2024 Jan;56(1):31-40. doi: 10.1055/a-2156-0063. Epub 2023 Aug 17.
Reference Type
RESULT
Raine T, Thomas JP, Brais R, Godfrey E, Carroll NR, Metz AJ. Test performance and predictors of accuracy of endoscopic ultrasound-guided fine-needle aspiration for diagnosing biliary strictures or masses. Endosc Int Open. 2020 Nov;8(11):E1537-E1544. doi: 10.1055/a-1231-4948. Epub 2020 Oct 21.
Reference Type
RESULT
Sadeghi A, Mohamadnejad M, Islami F, Keshtkar A, Biglari M, Malekzadeh R, Eloubeidi MA. Diagnostic yield of EUS-guided FNA for malignant biliary stricture: a systematic review and meta-analysis. Gastrointest Endosc. 2016 Feb;83(2):290-8.e1. doi: 10.1016/j.gie.2015.09.024. Epub 2015 Sep 28.
Reference Type
RESULT
Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015 Jan;81(1):168-76. doi: 10.1016/j.gie.2014.09.017. Epub 2014 Nov 1.
Reference Type
RESULT
Tummala P, Munigala S, Eloubeidi MA, Agarwal B. Patients with obstructive jaundice and biliary stricture +/- mass lesion on imaging: prevalence of malignancy and potential role of EUS-FNA. J Clin Gastroenterol. 2013 Jul;47(6):532-7. doi: 10.1097/MCG.0b013e3182745d9f.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUS-FNB biliary strictures
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy
NCT01678391
COMPLETED
NA
EUS Guided Drainage of Post Pancreatitis Pancreatic Fluid Collection
NCT06280248
NOT_YET_RECRUITING
NA
Endoscopic Ultrasound-guided Rendezvous Versus Precut Papillotomy
NCT06010576
RECRUITING
NA
Safety and Efficacy of EUS-RFA in the Treatment of Pancreatic Lesions: A Prospective Registry
NCT07136324
ACTIVE_NOT_RECRUITING
Prospective Comparison Between Ultra Early NKF Versus Standard Cannulation Alone
NCT04492137
UNKNOWN
NA
Prospective Registry Of Therapeutic EndoscopiC ulTrasound
NCT04813055
RECRUITING
The Economic Impact of the Pancreatography in the Endoscopic Treatment of Pancreatic Pseudocysts
NCT04494282
COMPLETED
NA
ERCP Biliary Cannulation Success Using ESGE Algorithm
NCT06380543
COMPLETED
EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis
NCT01774513
UNKNOWN
NA
Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter
NCT00160836
UNKNOWN
PHASE1
Comparison of Dual-lumen Catheter-guided Mini-forceps Biopsy and Brush Cytology with Vacuum Aspiration in Suspicious Biliary Strictures
NCT06612931
COMPLETED
NA
Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods
NCT01227382
COMPLETED
NA
Ultrasound Elastography for Prediction of Postoperative Pancreatic Fistula
NCT02589379
UNKNOWN
Microbiological Assessment of Bile in Patients Undergone to Endoscopic Retrograde Cholangiography (ERCP): the "Microbile Registry"
NCT06115564
UNKNOWN
ERCP With and Without EUS Guided HGS for Bilateral Biliary Decompression in Malignant Hilar Biliary Obstruction
NCT06613945
RECRUITING
NA
Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts
NCT02057146
COMPLETED
NA
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
NCT01643460
COMPLETED
NA
Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP
NCT03510754
COMPLETED
Los Angeles Prospective GI Biliary and EUS Series
NCT02196935
RECRUITING
EUS-Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy
NCT01678326
COMPLETED
NA
Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
NCT01238341
COMPLETED
Ultrasound-guided Percutaneous Biliary Drainage Versus Endoscopic Ultrasound-guided Biliary Drainage
NCT03546049
UNKNOWN
NA
EUS-guided Transenteric Drainage With a Novel Lumen-apposing Metal Stent
NCT03002051
COMPLETED
NA
Effect of Same-session EUS on ERCP in Pancreaticobiliary Diseases
NCT06978231
RECRUITING
NA